CCM
EDIT icon

CAAS Capital Management’s Editas Medicine EDIT Stock Holding History

CAAS Capital Management’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-140,500
Closed -$9.85M – 1216
2020
Q4 		$9.85M Buy
+140,500
New +$5.77M 0.09% 209

Other funds holding EDIT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

CAAS Capital Management's EDIT Position: Q3 2020 in Review

CAAS Capital Management sold out of Editas Medicine (EDIT) in Q3 2020, closing a stake of 1,396,053 shares — an estimated $41.3M sold.

CAAS Capital Management first reported a position in EDIT in Q2 2020 and held it in 1 quarter. The position peaked at $41.3M in Q2 2020. 239 funds tracked by Wall St. Rank hold EDIT as of Q3 2020.

  • CAAS Capital Management reported no remaining Editas Medicine position as of Q3 2020 after selling out during the quarter.
  • CAAS Capital Management sold 1,396,053 Editas Medicine shares in Q3 2020, an estimated $41.3M.
  • CAAS Capital Management first reported a position in Editas Medicine in Q2 2020 and held it in 1 quarter.
  • CAAS Capital Management's Editas Medicine position peaked at $41.3M in Q2 2020.
  • 239 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2020.

Based on CAAS Capital Management's 13F filing for Q3 2020, filed 9 Nov 2020.